- Novavax已要求联邦监管机构进行新的Covid-19疫苗的紧急使用授权。
- 同时，Sanofi和Glaxosmithkline要求对其Covid-19疫苗进行全面批准。
- Both vaccines use older technology than the mRNA vaccines currently in use.
- Experts say the new vaccines could help convince hesitant people to get vaccinated.
- 他们还指出，由于不需要在极低的温度下存储，因此新的疫苗可以在全球范围内提供帮助。
两种新的Covid-19疫苗可以帮助增加接种疫苗的人数，因为他们依靠更老，更熟悉的技术来防止新颖的冠状病毒。
制药公司Novavax目前是seeking食品药品监督管理局（FDA）的紧急使用授权（EUA）为其新疫苗提供了批准在加拿大和其他国家使用。
Sanofi和Glaxosmithkline（GSK）开发的另一种新疫苗最近完成了3期临床试验，并且正在提交for full approval from the FDA.
Unlike the Moderna and Pfizer-BioNTech vaccines, which use cutting-edgemRNA technology为了引起对冠状病毒感染的免疫反应，Novavax和Sanofi-GSK都是蛋白质辅助疫苗，并使用与流感疫苗相似的技术。
Rather than using genetic information to alert the immune system like an mRNA vaccine, Novavax and Sanofi-GSK tie a bit of harmless coronavirus spike protein to an adjuvant, an ingredient that alerts the immune system.
使用这种著名的疫苗技术可能会促使人们接种犹豫或反疫苗的人。Philip Felgner, PhD, director of the University of California at Irvine’s Vaccine Research and Development Center.
In the case of Novavax, the adjuvant is derived from tree bark.
SANOFI-GSK疫苗使用一种名为AS03的佐剂，该佐剂基于一种称为Sopalene的油，最初来自鲨鱼。
费尔格纳对Healthline表示：“我们已经有数数十年的AS03和数百万接受了接种疫苗的经验。”雷竞技app官网
自1950年代以来，辅助疫苗就已经存在，这也可以使“即使关心安全问题的人，即使mRNA疫苗非常安全，”Dr. Bob Bollinger，马里兰州约翰·霍普金斯大学医学院的传染病教授和Emocha Health的创始成员。
他告诉Healthline：“如果说服那些犹豫要接种疫苗的人，那是一件好事。”雷竞技app官网
The fact that Novavax is applying for an EUA from the FDA may not satisfy some vaccine-hesitant people, but the new vaccine from Sanofi-GSK checks the boxes of being a non-mRNA vaccine and having gone through the full FDA approval process.
In February, Sanofi-GSKannouncedthey had completed phase 3 clinical trials on their vaccine and will be submitting it to FDA for approval.
费尔格纳说：“自[大流行]开始以来，它一直在开发。”他还指出，如果没有FDA的紧急授权程序，仍然不会有任何Covid-19-19-19。
In a statement, Sanofi-GSK said their research showed the vaccine was 100 percent effective against severe COVID-19 disease and hospitalization, 75 percent effective against moderate or severe COVID-19 disease, and nearly 58 percent effective against any symptomatic COVID-19 disease.
费尔格纳说：“就疗效和安全性而言，这与mRNA疫苗非常相似。”
According to data from the美国人口普查局，对副作用的关注是未接种疫苗的美国成年人引用的主要原因。
对疫苗的不信任是疫苗犹豫的第二常见原因，其次是对政府的普遍不信任。
Felgner said the new vaccines likely won’t address all concerns about the side effects of the COVID-19 vaccine.
Among other things, adjuvants are known to cause pain at the site of injection, which is the most common side effect associated with the COVID-19 shots.
费尔格纳还指出，尽管拥有整个FDA批准过程的疫苗将是有价值的，但与数十亿接受mRNA疫苗的人相比，Sanofi-GSK在其临床试验中使用的参与者数量显得苍白。
布林格说，新的疫苗可能会消除拒绝接种疫苗的美国人人数，但最大的价值可能是全球性的。
与在低至-130°F的温度下必须存储的mRNA疫苗不同，新疫苗需要较少的极端冷藏。
“他们更容易生产,降低成本,和more easily transportable,” said Bollinger. “They’re really going to be useful in getting more of the world vaccinated, which is to everyone’s benefit.”